Clinical outcomes of umbilical cord blood transplantation for AML patients in the era of FLT3 inhibitors

JRCT ID: jRCT1031230158

Registered date:24/06/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Acute myeolid leukemia
• Date of first enrollment: 24/06/2023
• Target sample size: 200
• Study type: Observational

Outcome(s)

• Primary Outcome: 1-year-progression-free survival in AML patients after UCBT

Secondary Outcome

1- and 5-year-cumulative incidence of relapse after UCBT
1- and 5-year-cumulative incidence of NRM after UCBT
1- and 5-year-cumulative incidence of overall survival after UCBT
1- and 5-year-cumulative incidence of viral infection (CMV, EBV, HHV-6) after UCBT
1- and 5-year-cumulative incidence of acute GVHD after UCBT
1- and 5-year-cumulative incidence of chronic GVHD after UCBT

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Adult AML patients who received UCBT in Toranomon Hospital between January 1st, 2019 and December 31st, 2023.
• Exclude criteria: Patients who declared not to participate the study.

Related Information

• Primary Sponsor: Uchida Naoyuki
• Source(s) of Monetary Support: Astellas Investigator Sponsored Research,Astellas Pharma Inc.